[{"orgOrder":0,"company":"Astex Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Guadecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Astex Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Astex Pharmaceuticals \/ Otsuka Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals for Guadecitabine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Neither study met the primary endpoint of statistically significant (p <0.05) improvement in overall survival (OS) compared with the control arm of physicians’ choice of alternative therapy.

                          Brand Name : SGI-110

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 14, 2020

                          Lead Product(s) : Guadecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank